Health Care & Life Sciences » Biotechnology | BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. | Mutual Funds

Mutual Funds that own BioSpecifics Technologies Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
172,619
2.37%
14,652
0%
07/31/2018
iShares Russell 2000 ETF
116,640
1.6%
-63
0.01%
09/06/2018
DFA US Small Cap Portfolio
107,549
1.47%
4,738
0.03%
04/30/2018
Vanguard Extended Market Index Fund
65,929
0.9%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
55,784
0.77%
0
0.03%
09/06/2018
DFA US Micro Cap Portfolio
48,728
0.67%
1,400
0.03%
04/30/2018
Harbor Small Cap Growth Opportunities Fund
41,278
0.56%
-2,636
0.57%
01/31/2018
GS Funds - Global Small Cap Core Equity Portfolio
40,219
0.55%
0
0.38%
01/31/2018
Schwab Small Cap Equity Fund
33,812
0.46%
0
0.27%
06/30/2018
Royce Micro Cap Fund
32,600
0.45%
0
0.84%
06/30/2018

About BioSpecifics Technologies

View Profile
Address
35 Wilbur Street
Lynbrook New York 11563
United States
Employees -
Website http://www.biospecifics.com
Updated 07/08/2019
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its products include XIAFLEX, which is a treatment used for Dupuytren's contracture. The company was founded in 1990 and is headquartered in Lynbrook, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.